Summary
Extrapolation from one country to another concerning costs of treatment of essential hypertension has to be made with caution because of wide variation of socio-economic differences and governmental price setting attitudes. The worldwide antihypertensive drug market shows a strong increase in the last few years and reflects the evolution away from diuretics and toward the more expensive ACE inhibitors and calcium antagonists, with a decreasing percent market of betablockers and absolute stagnation in other antihypertensives outside these four groups of drugs.
References
Waeber B, Nussberger J, Brunner HR. Stratégie thérapeutique dans l'hypertension artérielle. Schweiz med Wschr 1987; 117:227–238.
Morant J. ed. Compendium suisse des médicaments 1988. Bale: Documed SA. 1987.
Chobanian AV. Hypertension, antihypertensive drugs, and atherogenesis. Mechanisms and clinical implications.J Clin Hypertens 1986; 2/3(suppl):148s-157s.
Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988; 259:1976–1982.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rutishauser, W.J. The costs of treatment of hypertension in Switzerland and Worldwide. Cardiovasc Drug Ther 3, 931–933 (1989). https://doi.org/10.1007/BF01869584
Issue Date:
DOI: https://doi.org/10.1007/BF01869584